16 Jun 2023 07:00
PRESS RELEASE
Ergomed Award of Share Options
Guildford, UK - 16 June 2023: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces that the following LTIP (Long Term Incentive Plan) awards were made to Jonathan Curtain (Chief Financial Officer) on 15 June 2023.
Mr Curtain was awarded a total of 28,866 options over the Company's ordinary shares. The options have an exercise price of 1 pence per share. Of the total option award to Mr Curtain, 75% will vest three years after the grant date, conditional upon the achievement of total shareholder return of 15% (compounded annual growth rate). The remaining 25% will vest three years after the grant date subject to continued employment. The option grant comprises annual discretionary LTIP awards for which Mr Curtain is eligible.
The notification below, made in accordance with the requirements of Article 19 of the UK Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
| ||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Jonathan Curtain | |
2 | Reason for the notification | ||
a) | Position/status | Chief Financial Officer | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Ergomed plc | |
b) | Legal Entity Identifier | 213800BVS8I9VMC1AP84 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Options over ordinary shares of 1 pence each
GB00BN7ZCY67 | |
b) | Nature of the transaction | Grant of options under the Company's Long Term Incentive Plan
| |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
1 pence
| 28,866 | ||
|
| ||
e) | Aggregated information - Aggregated volume - Price - Aggregated total | Options over 28,866 ordinary shares at an exercise price of 1 pence per share | |
f) | Date of the transaction | 15 June 2023 | |
g) | Place of the transaction | Outside a trading venue | |
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402 975
Dr Miroslav Reljanović (Executive Chairman)
Jonathan Curtain (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets and
Strategy)
Numis Securities Limited (Nominated Advisor and Joint Tel: +44 (0) 20 7260 1000
Broker)
Freddie Barnfield / Euan Brown/ Jack McLaren
Peel Hunt Securities Limited (Joint Broker) Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher Golden
Consilium Strategic Communications - for UK enquiries Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.